Heartland Cancer Research CCOP (Heartland) offers participation in NCI-sponsored cooperative group protocols in cancer treatment, control, and prevention research to the metropolitan and rural communities of Eastern and Central Missouri, including medically under-served rural communities. This research ultimately facilitates the introduction of newly developed cancer prevention strategies, early detection techniques, cancer treatment and symptom management interventions not only to these same populations, but also nationally. Heartland's main component, Missouri Baptist Medical Center (MBMC), has a long history of high-quality clinical oncology research. The elements of that research include: 1) 7 medical oncologists and associated professional staff with clinical trial experience, 2) diligent protection of human subjects according to federal regulations, 3) established, successful participant eligibility screening procedures, and 4) refined protocol compliance and data management procedures. Affiliates in Jefferson City (Capitol Region Medical Center) and Cape Girardeau, Missouri (Southeast Health) provide clinical trial participation opportunities to over 3 counties in rural Missouri. Heartland will maintain a wide menu of clinical trials in order that physicians will have a protocol available for the majority of their cancer patients. CRA and research nursing staff will facilitate the process of entering patients on study, assuring protocol compliance, and submitting data, specimens, and tissue in a timely basis. In addition to their accrual and data management efforts. Heartland members make contributions to the group life of the Alliance and NSABP through committee participation and ad hoc auditing. Heartland continues to expand the existing research program to a wide geographic area to Improve the cancer-related health of the suburban and rural communities served by the CCOP.

Public Health Relevance

Heartland was developed to reduce cancer incidence, morbidity, and mortality by accelerating the transfer of newly developed cancer treatment, and prevention and control interventions to the populace of St. Louis County and contiguous, medically under-served rural areas in Missouri. Through Heartland's network of clinics, clinical research access is provided to more than thirty counties in eastern, central, and southern Missouri that would not otherwise be available.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-B (J1))
Program Officer
Dimond, Eileen
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Missouri Baptist Medical Center
St. Louis
United States
Zip Code
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Gupta, Pankaj; Mulkey, Flora; Hasserjian, Robert P et al. (2013) A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs 31:1311-20
Ogino, Shuji; Shima, Kaori; Meyerhardt, Jeffrey A et al. (2012) Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 18:890-900
Romanus, Dorothy; Kindler, Hedy L; Archer, Laura et al. (2012) Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 43:205-17

Showing the most recent 10 out of 26 publications